# Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

> **NCT04851964** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 416 (actual)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **BIOLOGICAL:** Experimental: Tezepelumab
- **OTHER:** Placebo
- **DRUG:** Mometasone furoate or equivalent intranasal corticosteroid

## Key facts

- **NCT ID:** NCT04851964
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-22
- **Primary completion:** 2024-09-23
- **Final completion:** 2024-12-11
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04851964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04851964, "Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04851964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*